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Introduction: Cerebrospinal fluid (CSF) amyloid-beta 38 (Aβ38), 40 (Aβ40), 42 (Aβ42) and total tau (T-tau) are
finding increasing utility as biomarkers of Alzheimer’s disease (AD). The purpose of this study was to determine
whether measured CSF biomarker concentrations were affected by transfer of CSF between tubes, and whether
addition of a non-ionic surfactant mitigates any observed effects.
Methods: AD and control CSF was transferred consecutively between polypropylene tubes. Aβ peptides and T-tau
were measured with and without addition of Tween 20 (0.05%).
Results: Measured concentrations of Aβ42 decreased by approximately 25% with each consecutive transfer.
Measured concentrations of Aβ38 and Aβ40 were also observed to decrease significantly with each consecutive
transfer (approximately 16% loss per transfer). Measured concentrations of T-tau also decreased significantly, but at
much smaller magnitude than the Aβ peptides (approximately 4% loss per transfer). The addition of Tween
20 mitigated this effect in all samples.
Conclusions: Consecutive CSF transfer between tubes has a significant impact on the measured concentration of
all Aβ peptides, and significant effect of lesser magnitude on T-tau. This would be sufficient to alter biomarker ratios
enough to mislead diagnosis. The introduction of Tween 20 at the initial aliquoting stage was observed to
significantly mitigate this effect.Introduction
Cerebrospinal fluid (CSF) amyloid beta 38 (Aβ38), amyl-
oid beta 40 (Aβ40), amyloid beta 42 (Aβ42) and total tau
(T-tau) are protein biomarkers used in the clinical diagno-
sis and research analysis of, and drug development for,
Alzheimer’s disease (AD). Inter-site variation in the mea-
sured concentration of these proteins, even in the same
samples, is well-recognised. Known confounding factors
in the measurement of Aβ and tau concentrations include
delays in sample analysis [1], diurnal variation [2], CSF
contamination with blood or breakdown of the blood
brain barrier [3,4], choice of storage tube material [5,6]
and sample storage volume [7]. The hydrophobic nature
of Aβ42 and its propensity to be adsorbed to the walls of
collection containers, as well as to aggregate with itself
and other proteins [3], appears to make this peptide more
vulnerable to these influences than many other analytes.* Correspondence: j.toombs@ucl.ac.uk
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2014Following an anomalous decrease in assayed Aβ42
concentration in the same CSF between two laborator-
ies, an investigation was made to ascertain the cause. As
the CSF tested was the same this ruled out collection
factors as a likely variable. Additionally, both laborato-
ries had assayed the sample using the same protocol,
suggesting that differences in technique and timing,
though impossible to eliminate, should have been min-
imal. Based on the propensity for certain proteins to ad-
sorb to container surfaces it was hypothesised that, as
CSF is transferred between surfaces (for example, tubes)
the concentration of these proteins in solution would de-
crease. Given a standardised volume, it was also conjec-
tured that this concentration decrease would be linear,
with a relative proportion of the protein being lost at each
step. It was predicted that the Aβ peptides would behave
in this way, and that T-tau would not be significantly
affected. Furthermore, this study explored whether
such effects could be mitigated by pre-treating the
sample with a non-ionic surfactant (Tween 20, also knownl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and/or aggregation of Aβ42 [7-9].
Methods
Assays
Pilot
We conducted an initial pilot study to demonstrate proof
of concept, which was then followed by a larger experiment
consisting of three replicate rounds. All assays were run on
a Meso Scale Discovery 6000 platform. The pilot experi-
ment used MSD Human Aβ42 and MSD Human Total
Tau kits (Meso Scale Discovery, Gaithersburg, MD, USA).
Samples were added to Aβ42 and T-tau plates in triplicate.
Replication
The replication experiment used MSD Human Aβ42
(V-plex), MSD Human Total Tau kits (V-plex) and
MSD Aβ Peptide Panel 1 (this panel is a triplex assay
measuring Aβ38, Aβ40 and Aβ42 using 6E10 in com-
bination with neoepitope-specific antibodies to the dif-
ferent Aβ C-termini) (V-plex). V-plex refers to the
updated validation versions that superseded the same
kits used in the pilot at the time of these experiments.
Samples were added to T-tau and Aβ peptide plates in
duplicate. Each assay was repeated at 24 hour intervals
a total of three times. The kit manufacturer’s protocol
was followed for all pilot and replicate assays.
Sample pools
This study tested two pools of de-identified CSF. The
first was from a cohort of subjects with CSF biomarker
profiles consistent with AD pathology. The combination of
Aβ42 <530 ng/L and T-tau >350 ng/L taken together have
a sensitivity and specificity for diagnosing AD pathology of
approximately 90% [4]. The second pool was from non-AD
control (CTRL) CSF (biomarker concentrations within the
normal range: Aβ42 ≥530 ng/L and T-tau ≤350 ng/L).
These value ranges are based on Innogenetic’s INNOTEST
Aβ42 and hTau assays, respectively. Ethical approval was re-
ceived from the regional ethics board at the University of
Gothenburg for the CSF pools used in this study. Accord-
ing to Swedish legislation, informed consent is not required
for de-identified CSF samples.
Pilot
The two pools were provided, pre-mixed and pre-spun, by
the Clinical Neurochemistry Laboratory at the Sahlgrenska
University Hospital, Sweden, in Greiner Bio-one
(Frickenhausen, Germany) polypropylene (PP), sterile,
50 mL tubes (cat. 210261). Each pool was split into two
25 mL aliquots, 12.5 μL Tween 20 (0.05%) was intro-
duced to one aliquot, and the other was kept neat. From
these pools four 925 μL aliquots were derived – Neat AD
(NAD), Tween AD (TAD), Neat control (NCT), and Tweencontrol (TCT). These aliquots were stored in Sarstedt
(Nümbrecht, Germany), PP, DNase/RNase free, 2 mL screw
top tubes (cat. 72.694.406).
Replication
Two pools of CSF were provided by the Clinical
Neurochemistry Laboratory at the Sahlgrenska University
Hospital, Sweden. These pools were not of the same CSF as
those used in the pilot, but met the same criteria for AD
and CTRL detailed above. Samples were received in eight
Sarstedt 10 mL, screw cap, PP tubes (cat: 62.9924.284), four
AD and four CTRL. Both AD and CTRL pools were treated
by the same procedure which follows, and is illustrated in
Figure 1. The four original sample tubes were thawed at
room temperature for one hour, then pooled together
into a 100 mL Sarstedt PP beaker (cat. 75.1354.001).
The mixed CSF was then transferred into a 50 mL Greiner
tube and then spun at 3,000 rpm for 10 minutes at 4°C
(the same method used in the pilot). Two 10 mL aliquots
were then created in empty 50 mL Greiner tubes. A total
of 5 μL of Tween 20 (0.05%) was added to one of these
newly created tubes. These 10 mL aliquots were each di-
vided into 1 mL aliquots to form neat and Tween storage
tube batches. The tubes used for storage were the same as in
the pilot. The result of this process was ten 1 mL aliquots of
four different types – Neat AD (NAD), Tween AD (TAD),
Neat control (NCT), and Tween control (TCT). The word
‘neat’ is used in this paper to distinguish the sample which
did not contain Tween 20, it does not denote dilution.
Sample treatment
Pilot
At the start of the experiment, the four sample aliquots
(NAD, TAD, NCT, TCT) were thawed together at room
temperature for approximately one hour. A portion of CSF
from each was then transferred consecutively to seven
other tubes. Starting with Tube 0 (the storage aliquot) with
925 μL, 710 μL was transferred to Tube 1; 510 μL was then
transferred from Tube 1 to Tube 2; 310 μL from Tube 2
to Tube 3; and 110 μL from Tube 3 to Tube 4. Thus,
the volumes in the experiment aliquots were as follows:
Tube 0 = 215 μL, Tube 1 = 200 μL, Tube 2 = 200 μL,
Tube 3 = 200 μL, and Tube 5 = 110 μL. Tube 5 had a lower
volume due to total volume restrictions. Aβ42 and T-tau
aliquots were dispensed into the same disposable PP plate
for dilution at factors 1:8 and 1:2, respectively.
Replication
It was recognised that the transfer volumes used in the
pilot were inconsistent and that this was a flaw in its
design. Therefore, these were adjusted in the replica-
tion study to be uniform. Additionally, three extra
transfer steps were included in the transfer series of
the replication. At the start of the experiment the four
Figure 1 Diagram showing the sample preparation process conducted for the replication experiment. The same process was used in the
pilot with the exception of different volumes, as detailed in the Methods section.
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together at room temperature for approximately one
hour. A portion of CSF from each was then transferred
consecutively to seven other tubes, leaving 100 μL in
each (Figure 1). Starting with Tube 0 (the storage aliquot)
with 1,000 μL, 900 μL was transferred to Tube 1; 800 μL
was then transferred from Tube 1 to Tube 2 and so on
until 200 μL was transferred from Tube 7 to an eighth
tube not used in the study; thus, the tubes used in the
experiment (tubes 0 to 7) each contained 100 μL of
pooled CSF. After the creation of this transfer series,
the samples had their anonymised identifiers (for example,
NAD1, NAD2 and so on) obscured by tape and were
rearranged and relabelled 1 to 32 (that is, eight tubes
for each of NAD, TAD, NCT and TCT) by a colleague
not otherwise participating in the study. Thus blinded,
sample aliquots were dispensed into a disposable PP
plate for dilution. This had not been done in the pilot. The
used tubes were kept in the order they were aliquoted
to the plate. After the data had been collected the tape
was removed and the identifiers matched with their
respective plate wells (for sample identification please
see Additional file 1). Dilution factors for Aβ42, T-tau and
Aβ Peptide Panel assays were 1:8, 1:4 and 1:2, respectively,
as recommended by the kit protocol. The dilution factor
for T-tau differed from the pilot due to volume restrictions
imposed by the 100 μL transfer volume.
All solutions, in both the pilot and replication, were
mixed by uninterrupted vortexing for five seconds, and
all pipette tips were pre-wetted with three pumps.Statistical analysis
Linear regression was used to examine the relationship
between analyte concentration values and number of sam-
ple transfers. The median of the measured analyte concen-
tration values was the dependent variable, and the number
of transfers was the independent variable of interest. In
the replication study, day (that is, assay repeat) was in-
corporated as a covariate. All statistical analyses were
conducted in Stata Version 12.1. Graphs were created
using SPSS version 21.
Results
Aβ42 pilot
Figure 2A shows the results of the pilot study for an Aβ42
single-plex assay. One transfer of neat AD CSF predicted a
change in measured Aβ42 concentration of −36.2 pg/mL,
(95% confidence interval (CI): −47.2 to −25.1 pg/mL,
P = 0.002). The average percentage difference per trans-
fer was 27.0% of the starting value. For neat control
CSF this predicted change was −72.1 pg/mL (CI: −78.4
to −65.8 pg/mL, P = <0.005). The average percentage
difference per transfer was 28.6%. Tween 20 acted to
mitigate the magnitude of this decrease in both pools. One
transfer of AD CSF in the presence of Tween 20 predicted
a change in measured Aβ42 concentration of −9.9 pg/mL
(CI: −16.6 to −3.2 pg/mL, P = 0.018). The average percent-
age difference per transfer was 5.1%. For control CSF with
added Tween the trend was a non-significant −27.2 pg/mL
(CI: −70.7 to +16.3 pg/mL, P = 0.14). The average per-
centage difference per transfer was 4.9%.
Figure 2 Effect of consecutive tube transfer on Aβ42. A) Pilot single-plex: data represent one assay. Neat CSF Aβ42 concentration decreases
linearly with consecutive transfer between tubes. Tween 20 mitigates concentration decrease in the same CSF. Lines of the same type represent
within plate replicates. B) Replication single-plex: data represent three assays. Neat CSF Aβ42 concentration generally decreases linearly with
consecutive transfer between tubes. Concentration reduction at the first transfer step is non-linear. Tween 20 mitigates concentration decrease in
the same CSF. Lines of the same type represent within and between plate replicates, separate days are not distinguished. C) Replication triplex:
data represent three assays. Neat CSF Aβ42 concentration generally decreases linearly with consecutive transfer between tubes. Concentration
reduction at the first transfer step is non-linear. Tween 20 mitigates concentration decrease in the same CSF. Lines of the same type represent
within and between plate replicates, separate days are not distinguished. Aβ42, amyloid beta 42; CSF, cerebrospinal fluid.
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Figure 2B presents the data for the single-plex Aβ42 over
three separate assays. Over seven transfers, one transfer
of neat AD CSF predicted a change in measured Aβ42
concentration of −37.3 pg/mL (CI: −40.6 to −28.3 pg/mL,
P = <0.005). The average percentage difference per trans-
fer was 21.1% of the starting value. For neat controlCSF this predicted change was −52.2 pg/mL (CI: −64.8
to −39.7 pg/mL, P = <0.005). The average percentage
difference per transfer was 22.7%. Tween 20 acted to
mitigate the magnitude of this decrease in both pools.
One transfer of AD CSF with Tween 20 predicted a
change in measured Aβ42 concentration of −25.2 pg/mL
(CI: −29.5 to −20.9 pg/mL, P = <0.005). The average
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CSF with added Tween one transfer predicted a change in
measured Aβ42 concentration of −34.0 pg/mL (CI: −44.9
to −23.1 pg/mL, P = <0.005). The average percentage
difference per transfer was 8.0%.
Aβ42 (triplex) replication
Figure 2C presents the data for the triplex Aβ42 over
three separate assays. Over seven transfer steps, one trans-
fer of neat AD CSF predicted a change in measured Aβ42
concentration of −34.9 pg/mL (CI: −40.9 to −28.8 pg/mL,
P = <0.005). The average percentage difference per transfer
was 22.2% of the starting value. One transfer of neat control
CSF predicted a change in measured Aβ42 concentration
of −41.4 pg/mL (CI: −62.0 to −40.9 pg/mL, P = <0.005).
The average percentage difference per transfer was 23.4%.
Tween 20 acted to mitigate the magnitude of this decrease
in both pools. In AD CSF with Tween 20 one transfer step
predicted a concentration change of −17.3 pg/mL (CI: −20.7
to −13.9 pg/mL, P = <0.005). The average percentage dif-
ference per transfer was 4.9%. In control CSF with Tween
20 one transfer step predicted a concentration change
of −28.1 pg/mL (CI: −32.6 to −23.7 pg/mL, P= <0.005). The
average percentage difference per transfer was 5.5%.
Aβ38 (triplex) replication
Figure 3A presents the data for the triplex Aβ38 over three
separate assays. Over seven transfer steps, one transfer ofFigure 3 Effect of consecutive tube transfer on Aβ38 and Aβ40. A) Re
decreases linearly with consecutive transfer between tubes. Tween 20 mitig
type represent within and between plate replicates, separate days are not
Aβ40 concentration decreases linearly with consecutive transfer between t
Lines of the same type represent within and between plate replicates, sepa
beta 40; CSF, cerebrospinal fluid.neat AD CSF predicted a change in measured Aβ38 con-
centration of −330.2 pg/mL (CI: −359.3 to −301.0 pg/mL,
P = <0.005). The average percentage difference per transfer
was 16.0% of the starting value. One transfer of neat control
CSF predicted a change in measured Aβ38 concentration
of −224.0 pg/mL (CI: −241.8 to −206.3 pg/mL, P = <0.005).
The average percentage difference per transfer was 16.1%.
Tween 20 acted to mitigate the magnitude of this decrease
in both pools. In AD CSF with Tween 20 one transfer
step predicted a concentration change of −53.1 pg/mL
(CI: −78.9 to −27.3 pg/mL, P = <0.005). The average
percentage difference per transfer was 1.4%. In control
CSF with Tween 20 one transfer step predicted a concen-
tration change of −38.4 pg/mL (CI: −53.5 to −23.4 pg/mL,
P = <0.005). The average percentage difference per trans-
fer was 1.1%.
Aβ40 (triplex) replication
Figure 3B presents the data for the triplex Aβ40 over three
separate assays. Over seven transfer steps, one transfer of
neat AD CSF predicted a change in measured Aβ40 con-
centration of −676.5 pg/mL (CI: −724.7 to −628.2 pg/mL,
P = <0.005). The average percentage difference per transfer
was 15.6% of the starting value. One transfer of neat control
CSF predicted a change in measured Aβ40 concentration
of −513.3 pg/mL (CI: −554.0 to −472.7 pg/mL, P = <0.005).
The average percentage difference per transfer was 17.5%.
Tween 20 acted to mitigate the magnitude of this decreaseplication: data represent three assays. Neat CSF Aβ38 concentration
ates the concentration decrease in the same CSF. Lines of the same
distinguished. B) Replication: data represent three assays. Neat CSF
ubes. Tween 20 mitigates the concentration decrease in the same CSF.
rate days are not distinguished. Aβ38, amyloid beta 38; Aβ40, amyloid
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step predicted a concentration change of −121.5 pg/mL
(CI: −174.7 to −68.4 pg/mL, P = <0.005). The average
percentage difference per transfer was 1.2%. In control CSF
with Tween 20 one transfer step predicted a concentra-
tion change of −112.9 pg/mL (CI: −152.2 to −73.6 pg/mL,
P = <0.005). The average percentage difference per transfer
was 1.6%.
T-tau pilot
Figure 4A shows that the concentration of T-tau did not
decrease significantly with consecutive transfer of CSF
between tubes: there was a trend for a decline in mea-
sured T-Tau concentration in neat AD and control
CSF (−93.8 pg/mL, CI: −194.9 to +7.3, P = 0.060, 5.1%;
and −34.5 pg/mL, CI: −73.3 to +4.3 pg/mL, P = 0.066,
5.8% respectively), but no evidence for a decline with
measured T-Tau concentration in AD and control CSF with
Tween (14.2 pg/mL, CI: −94.7 to +123.1 pg/mL, P = 0.706,
0.4%; and −14.8 pg/mL, CI: −38.8 to +10.0 pg/mL, P =
0.157, 1.6% respectively).
T-tau replication
Figure 4B demonstrates the data for T-tau over three
separate assays. Over seven transfers, one transfer of
neat AD CSF predicted a change in measured T-Tau
concentration of −24.5 pg/mL (CI: −39.4 to −9.5 pg/mL,
P= 0.003). The average percentage difference per transferFigure 4 Effect of consecutive tube transfer on total tau. A) Pilot: data
did not decrease significantly with consecutive transfer between tubes. Sam
replicates. B) Replication: data represent three assays. Neat CSF T-tau conce
tubes. Tween CSF T-tau was not significantly affected by consecutive transf
represent within and between plate replicates, separate days are not distinwas 4.4% of the starting value. For neat control CSF this pre-
dicted change was −11.6 pg/mL (CI: −17.4 to −5.9 pg/mL,
P = <0.005). The average percentage difference per transfer
was 3.5%. One transfer of AD CSF with Tween 20 did
not demonstrate a significant change in measured T-Tau
concentration; T-Tau: −1.6 pg/mL (CI: −7.4 to +4.1 pg/mL,
P = 0.558). The average percentage difference per trans-
fer was 0.2%. For control CSF with added Tween one
transfer did not predict a significant change in measured
T-Tau concentration: −0.4 pg/mL (CI: −4.0 to +3.2 pg/mL,
P = 0.828). The average percentage difference per transfer
was 0.5%.
All results are summarised in Table 1. All data points
were detected within the standard range of the calibration
curves (see Additional files 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12).
Discussion
Aβ42
This study demonstrates that the consecutive transfer
of CSF samples between tubes has significant impact
on the measured concentration of Aβ42. Figure 2A re-
veals the potential for concentration levels in neat CSF
pools to be artificially reduced from within the ‘normal’
(that is, CTRL) range to pathological levels in three
tube transferals. In a different CSF pool, tested three
times (in two different assay kits), this was the case in
just one transfer (Figure 2B and C). This difference be-
tween transfer steps 0 to 1 is interesting. It is possiblerepresent one assay. Neat and Tween control CSF T-tau concentration
ples were diluted 1:2. Lines of the same type represent within plate
ntration decreased significantly with consecutive transfer between
er between tubes. Samples were diluted 1:4. Lines of the same type
guished. CSF, cerebrospinal fluid; T-tau, total tau.
Table 1 Summary of results
Analyte Pool type Linear regression
(four transfers)
Confidence
interval
P %
change
Linear regression
(seven transfers)
Confidence
interval
P %
change
(Pilot) Neat AD −36.2 −47.2 to −25.1 0.002 27.0%
Tween Ad −9.9 −16.6 to −3.2 0.018 5.1%
Aβ42 (Single-plex) Neat CTRL −72.1 −78.4 to −65.8 <0.005 28.6%
Tween CTRL −27.2 −70.7 to 16.3 0.140 4.9%
(Pilot) Neat AD −93.8 −194.9 to 7.3 0.060 5.1%
Tween Ad 14.2 −94.7 to 123.1 0.706 0.4%
T-tau Neat CTRL −34.5 −73.3 to 4.3 0.066 5.8%
Tween CTRL −14.8 −38.8 to 10.0 0.157 1.6%
(Replication) Neat AD −50.2 −62.6 to −37.9 <0.005 21.8% −34.3 −40.6 to −28.3 <0.005 21.1%
Tween Ad −22.1 −31.3 to −12.9 <0.005 6.1% −25.2 −29.5 to −20.9 <0.005 7.8%
Aβ42 (Single-plex) Neat CTRL −83.3 −110.0 to −56.5 <0.005 25.6% −52.2 −64.8 to −39.7 <0.005 22.7%
Tween CTRL −9.8 −22.8 to 3.2 0.126 1.9% −34 −44.9 to −23.1 <0.005 8.0%
(Replication) Neat AD −16.9 −31.7 to −2.2 0.028 2.6% −24.5 −39.4 to −9.5 0.003 4.4%
Tween Ad 7.1 −3.4 to 17.6 0.164 −0.9% −106 −7.4 to 4.1 0.558 0.2%
T-tau Neat CTRL −3.35 −11.6 to 4.9 0.338 −0.1% −11.6 −17.4 to −5.9 <0.005 3.5%
Tween CTRL 1.1 −7.5 to 9.6 0.789 −0.5% −0.4 −4.0 to 3.2 0.828 0.5%
(Replication) Neat AD −320.1 −397.0 to −243.1 <0.005 11.7% −330.2 −359.3 to −301.0 <0.005 16.0%
Tween Ad −37.7 −103.3 to 27.8 0.232 0.4% −53.1 −78.9 to −27.3 <0.005 1.4%
Aβ38 (Triplex) Neat CTRL −215.9 −262.5 to −169.3 <0.005 11.7% −224.0 −241.8 to −206.3 <0.005 16.1%
Tween CTRL 5.1 −16.2 to 26.4 0.608 −0.3% −38.4 −53.5 to −23.4 <0.005 1.1%
(Replication) Neat AD −669.9 −786.7 to −552.9 <0.005 12.1% −676.5 −724.7 to −628.2 <0.005 15.6%
Tween Ad 15.3 −66.7 to 97.4 0.689 −0.6% −121.5 −174.7 to −68.4 <0.005 1.2%
Aβ40 (Triplex) Neat CTRL −55.1 −652.1 to −449.9 <0.005 14.5% −513.3 −554.0 to −472.7 <0.005 17.5%
Tween CTRL −20.5 −76 to 35 0.434 0.1% −112.9 −152.2 to −73.6 <0.005 1.6%
(Replication) Neat AD −47.7 −61.6 to −33.8 <0.005 21.0% −34.9 −40.9 to −28.8 <0.005 22.2%
Tween Ad −10.9 −18.7 to −3.2 0.010 1.9% −17.3 −20.7 to −13.9 <0.005 4.9%
Aβ42 (Triplex) Neat CTRL −74.6 −99.0 to −50.2 <0.005 23.1% −41.4 −62.0 to −40.9 <0.005 23.4%
Tween CTRL −19.6 −27.0 to −12.2 <0.005 3.1% −28.1 −32.6 to −23.7 <0.005 5.5%
The table summarises the results of linear regression and percentage difference calculations for all analytes assayed in this study. Linear regression used the
median values of the measurements made at each transfer step. ‘% change’ represents the average of the percentage difference between each of the relevant
number of transfer steps. Bold text is used as a visual aid and has no other meaning. Aβ, amyloid beta; AD, Alzheimer’s disease; CTRL, control, T-tau, total tau.
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transfer tube 1 in the pilot study could have had an
impact on this result. However, this is considered un-
likely for reasons discussed below. Alternative sugges-
tions could be that there was a fault with pilot tube 0
(given the close similarity between results in the six
independent tubes used in the replication rounds it
seems unlikely a fault lay there), an anomaly caused by
human or detection error (once again it seems more
reasonable to suspect the pilot result), or a difference
in the pool matrices which may have altered the be-
haviour of the analyte in the conditions of the first
transfer step. When the Aβ42 results for the neat AD
and CTRL pools of the pilot study and the replicationstudy (single-plex and triplex) are compared over the
next three transfer steps (Figure 2) a linear trend can
be observed between steps 2 to 4. Furthermore, this trend
was demonstrated to continue over steps 5 to 7 in the repli-
cation rounds. Table 1 demonstrates very comparable linear
regression results, with strongly overlapping confidence
intervals, for all Aβ42 assays conducted.
The addition of the non-ionic surfactant Tween 20
to pooled samples prior to aliquoting had a mitigating
effect on the reduction in measured Aβ42 over the
transfer series, although reduction was still significant.
The storage concentration of Tween 20 used in this study
was 0.05% and after 1:8 sample dilution would have been
approximately 0.006%. The generally accepted critical
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but micelle formation has been shown to initiate at
0.002% [10]. This suggests that many of the Tween 20
molecules in our samples would still be expected to be
in a micelle arrangement during the assay [8] and, as
such, be in competition for tube surface and liquid/air
interface distribution with other hydrophobic molecules.
It has been shown that Tween 20 may also prevent oligo-
merisation of Aβ42 [9] and this may apply to aggregation
more generally. Our study does not elucidate the relative
involvement of the two potential mechanisms. Figure 2
and Table 1 show that treating samples with Tween 20
significantly reduced concentration loss per transfer
step, relative to their neat counterpart. However, it is
worth noting that a dramatic decrease in concentration
was observed between transfer steps 5 to 7 in the TCT
pool of the replication study. This would be consistent
with a decrease in the concentration of Tween 20 molecules
(either by complete loss of all Tween 20 molecules or con-
centration falling far enough below the CMC that micelle
numbers no longer formed effective surface competition)
sufficient to allow Aβ42 adsorption comparable to that
in neat CSF. This effect was not observed in any other
pool, but consistent replication (CV% at Transfer 6 = 3.1%,
at Transfer 7 = 19.0%) suggests it is unlikely to be an
error artefact.
Aβ38
Data show that the consecutive transfer of CSF samples
between tubes has a significant impact on the measured
concentration of Aβ38. Figure 3 and Table 1 show a
strong linear tendency for concentration reduction in
neat CSF. This effect was greatly mitigated in the same
samples treated with Tween 20. Over four transfer steps
reduction did not reach significance in Tween treated
samples, but over all seven steps significant reduction
was observed.
Aβ40
This study demonstrates that the consecutive transfer of
CSF samples between tubes has a significant impact on
the measured concentration of Aβ40. Figure 3 and
Table 1 show a strong linear tendency for concentra-
tion reduction in neat CSF. This effect was greatly mit-
igated in the same samples treated with Tween 20. As
with Aβ38, over four transfer steps reduction did not
reach significance in Tween treated samples, but over
all seven steps significant reduction was observed. It is
interesting to note that the starting concentration of
Aβ40 was nearly twice that of Aβ38 and, accordingly,
linear regression is calculated to follow the same rela-
tionship. This demonstrates the apparent concentra-
tion dependency of transfer loss rather acutely and is a
trend observed in all other analytes.T-tau
Data show that consecutive transfer of CSF samples
between tubes had a much smaller effect on T-tau
concentrations than on the Aβ peptides. The results of
the pilot showed a non-significant trend for a reduc-
tion in concentrations of T-tau in neat CSF and no
evidence of a reduction following the addition of
Tween 20. However, the P values for neat AD (P = 0.06)
and control (P = 0.066) pools approached significance.
Due to the difference in dilution factor between the pilot
(1:2) and the replication study (1:4), and given the apparent
tendency for protein loss to be concentration dependent,
results may not be directly comparable between the two
studies. The replication study showed significant reduction
in T-tau concentration over seven transfer steps in both
neat pools (Figure 4, Table 1). The NAD pool of the replica-
tion study reached significant reduction over the initial four
transfer steps, thus providing a case that T-tau can be
affected within this number of transfers. Tween 20 CSF
pools remained unaffected even over the seven transfer
steps. Compared with Aβ peptides, neat and Tween
20 T-tau results show a proportionally lower rate of
concentration reduction per transfer step (Table 1).
Transferring CSF between multiple surfaces could,
therefore, create an artificially low Aβ42 to T-tau ratio
and risk false positive diagnosis of AD in patients and
research participants.
The transfer effects we observed – principally for Aβ
peptides, but also, to a lesser extent, for T-tau measure-
ment – may well have significant influences in practice.
Not only individual levels of these analytes, but also the
ratio of T-tau to Aβ42 are used in clinical and research
criteria contributing to diagnosis of AD [11]. Additionally,
it is possible that Aβ peptide ratios could be altered
over a number of transfers, given the smaller percent-
age decrease in peptides 38 and 40 relative to 42, or by
the potential for non-linear reduction, despite a com-
mon linear tendency.
Potential confounds
Volume
In a previous study [7], we identified sample volume
as a potential confound to the measurement of Aβ42
concentration but not T-tau. There were inter-study
volume differences between the pilot and the replica-
tion studies and intra-study volume differences in the
pilot alone.
In the pilot, although the volume and, therefore, the
surface area, of each sample was equivalent in storage
(925 μL), it was not possible to maintain consistent
200 μL volume between all the transferral stage ali-
quots. Based on the previous data (0.8 pg/mL increase
per 10 μL increase in control CSF Aβ42, 0.74 pg/mL in-
crease per 10 μL increase in AD CSF Aβ42) the following
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at 200 μL:
Aβ42 Tube 0 (215 μL):
Predicted: Control ¼ þ1:2 pg=mL;AD ¼ þ1:11 pg=mL
Aβ42 Tube 4 (110 μL):
Predicted: Control ¼ −7:2 pg=mL;AD ¼ −6:66 pg=mL
Therefore, volume effects are not likely to have been
significantly above noise and thus sufficient to bias the
results of this study.
In the replication study storage aliquots were 1000 μL
and transfer aliquots were kept equal at 100 μL so as to
exclude any effect on volume. It should be noted that the
samples used in the pilot and replication studies were of
different pools, and the comparisons of this study are
based on proportional concentration loss not absolute
values. Direct comparisons of Aβ42 between the pilot
and replication study are not likely to be valid.
pH
Murphy et al. [12] have identified that short term storage
of CSF samples on dry ice can lower the sample pH
through intrusion of CO2. pH change can affect the
‘tertiary and quaternary structure, enzymatic rate con-
stants, solubility, tendency to aggregate, susceptibility
to chemical degradation and propensity to adsorb to
surfaces’ of constituent proteins [12]. In our study the
original, large volume samples were transported between
the Sahlgrenska and London laboratories on dry ice. Once
in London they were thawed, divided into aliquots and
not subsequently exposed to dry ice. Our results are not,
therefore, attributable to this effect.
Further work
Standard procedure for CSF collection by lumbar puncture
[13] (However, it should be noted that touching any part
other than the plastic head of the needle may raise sterilisa-
tion issues) involves the fluid being passed typically through
a 20- to 22-gauge spinal needle (sometimes with a catheter)
and dripped into a collection tube. In some cases, and in
some centres, CSF is aspirated using a syringe. Baseline and
diagnostic tests may then be run on the sample, before it is
aliquoted into smaller volume storage tubes. Thus, CSF can
encounter two or three different containers before reaching
clinical diagnostics, and three or four or more before reach-
ing storage for research or re-testing. Figures 2, 3 and 4
collectively show that this could lead to compromised
diagnoses, misleading research data and discrepancy be-
tween results. Further attention needs to be directed toward
how every step of collection may compromise the accuracyof current assays relative to in vivo reality. A number of
these issues have been addressed in other studies [3,14].Conclusions
Aβ42, Aβ42:T-tau ratio and Aβ38:40:42 ratio are now
widely used to help diagnose Alzheimer’s disease pathology
in individuals with cognitive impairment. Between lumbar
puncture and laboratory analysis, CSF can be transferred to
different containers a number of times, frequently unknown
to scientists running the assays, and potentially different
between individuals and between sites. We have shown
that Aβ42 can be reduced by approximately 25% simply
through tube transfer. Effort should be made to minimise
multiple transfers of CSF between surfaces, and record
how many such steps a sample has gone through. The
addition of 0.05% Tween 20 to aliquots at initial sample
storage may mitigate at least some of these effects and
should be the subject of further study.Additional files
: Unblind. Original sample ID’s matched with their
blinded aliases.
: Pilot Ab42. Assay raw data.
: Pilot Ttau. Assay raw data.
: Replication Ab42 #1. Assay raw data.
: Replication Ab42 #2. Assay raw data.
: Replication Ab42 #3. Assay raw data.
: Replication Ttau #1. Assay raw data.
: Replication Ttau #2. Assay raw data.
: Replication Ttau #3. Assay raw data.
: Ab triplex #1. Assay raw data.
: Ab triplex #2. Assay raw data.
: Ab triplex #3. Assay raw data.
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